Update shared on21 Sep 2025
Fair value Increased 5.88%Despite a slight downgrade in consensus revenue growth forecasts, a higher forward P/E multiple has driven the consensus Analyst Price Target for Healthcare Services Group up from $17.00 to $18.00.
What's in the News
- Repurchased 566,997 shares for $7.6 million in the latest tranche, completing 2,690,108 shares for $30.67 million under the buyback program.
- Actively seeking acquisitions and remains committed to capital allocation for organic growth, acquisitions, and opportunistic share repurchases; no acquisitions completed in the quarter.
- Reiterated 2025 guidance for mid-single digit growth.
- Added to multiple Russell growth and small-cap indexes, including Russell 3000 Growth, 2000 Growth, 2500 Growth, and related benchmarks.
Valuation Changes
Summary of Valuation Changes for Healthcare Services Group
- The Consensus Analyst Price Target has risen from $17.00 to $18.00.
- The Future P/E for Healthcare Services Group has risen from 11.63x to 12.31x.
- The Consensus Revenue Growth forecasts for Healthcare Services Group has fallen from 5.9% per annum to 5.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.